Brief: Elutia Announces FDA Clearance Of Elupro In Patients With Implantable Cardiac Pacemakers And Defibrillators
17/06/2024 13:06
June 17 (Reuters) - Elutia Inc ELUT.O :
* ELUTIA ANNOUNCES FDA CLEARANCE OF ELUPRO®: THE FIRST
ANTIBIOTIC-ELUTING BIOENVELOPE DESIGNED TO PROTECT PATIENTS WITH
IMPLANTABLE CARDIAC PACEMAKERS AND DEFIBRILLATORS
* ELUTIA PLANS NATIONWIDE ELUPRO LAUNCH IN H2 2024
Source text for Eikon: ID:nGNX4Qlgvr
Further company coverage: ELUT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Elutia
See all newsBrief: Elutia Receives $8 Million Payment From Boston Scientific Company Now Fully Funded Into 2029
Elutia Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Elutia Secures $15 Million Loan Financing From Avenue Capital Group
Elutia's Q2 revenue falls on SimpliDerm production disruption
Elutia Inc expected to post a loss of 15 cents a share - Earnings Preview